Clene Nanomedicine
Manufacturing · Utah, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
6550 S Millrock Dr Ste G50, Salt Lake Ci...Phone Number
(801) 676-9695Website
www.clene.comRevenue
<$5 MillionStock Symbol
CLNNIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Clene Nanomedicine
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectiousRead more
Clene Nanomedicine Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Clene Nanomedicine your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Clene Nanomedicine has new funding data
Earning: See what the market has to say on Clene Nanomedicine recently announced quarterly report
Website visits: Recent activity has been detected on your website
Clene Nanomedicine, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Clene Nanomedicine has recently received funding, and reach out quickly before it becomes old news!
Click to see if Clene Nanomedicine had a recent Job posting/layoffs
Check out if Clene Nanomedicine is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Clene Nanomedicine launches new products
Congratulate Masked Content for being promoted to Masked Content at Clene Nanomedicine
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Clene Nanomedicine
Compare insights from companies similar to Clene Nanomedicine, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Clene Nanomedicine is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Clene Nanomedicine is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Clene Nanomedicine.
Clene Nanomedicine financials insights
Gather financial insights about Clene Nanomedicine, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Series A
$31.6M
2016
Series B
$17M
2020
Debt
$350K
Series D
$42.5M
2023
Other Financing Round
$40M
2024
Other Financing Round
$7.3M
2025
Stock/Share Issuance
$1.5M
Clene Nanomedicine Tech Stack
A closer look at the technologies used by Clene Nanomedicine
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Clene Nanomedicine has highlighted that, unlike an existing FDA-approved SOD1 ALS asset that achieved a 55% neurofilament reduction without demonstrated clinical benefit, its drug candidate targets 98% to 99% of all ALS patients and has confirmed that its more modest 10% neurofilament light reduction is directly tied to clinical benefit.
Medical Research, Pharmaceuticals
Project
Clene Nanomedicine has disclosed that the FDA has requested the inclusion of data from its VISIONARY-MS phase II program in the ALS NDA filing, with a separate regulatory discussion for the MS indication ongoing with the FDA's Division of Neurology I under CDER.
Pharmaceuticals, Regulations
Project
Clene Nanomedicine has reported that its ALS drug candidate demonstrated a 38% lower risk of death (P=0.037) over a four-year assessment period with randomized concurrent controls, and, among patients with neurofilament light decline or stabilization, statistically significant improvements in ALSFRS functional scores (P=0.03) and slow vital capacity breathing capacity (P=0.003).
Medical Research, Pharmaceuticals
Project
Medical Research, Pharmaceuticals
Clene Nanomedicine News & Media
Clene Announces Closing of $4 Million Registered Direct Offering Extending Capital Runway Beyond FDA Decision on CNM-Au8® NDA
SALT LAKE CITY, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN), a clinical-stage biotechnology company focused on ALS, today announced the closing of a registered direct offering of common stock to existing shareholders, including insiders, with total gross proceeds of $4 million.Clene Announces $4 Million Registered Direct Offering
SALT LAKE CITY, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN), a clinical-stage biotechnology company focused on ALS, today announced the pricing of a registered direct offering of 1,219,513 shares at a purchase price of $3.28 per share to existing shareholders, including insiders, with total gross proceeds of $4 million. The offering is expected to close on September 17, 2026.Clene to Present at Upcoming September Investor Conferences
SALT LAKE CITY, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) today announced that management will present at the 2026 Cantor Global Healthcare Conference and at the H.C. Wainwright 28th Annual Global Investment Conference and host 1x1 investor meetings at both conferences.Clene to Present at the Emerging Growth Conference
SALT LAKE CITY, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) today announced that management will present at the Emerging Growth Conference.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Clene Nanomedicine
Sign Up For FreeTo access detailed company insights
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au... Read More
